Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator’s choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL).

Adrienne Alise Phillips,Paul Fields,Maria L Delioukina,Steven M Horwitz,Karen M Dwyer,Dmitri O Grebennik,Stefan K Barta,Jean Cãƒâ´Me Meniane,Kevin Conlon,Graham Taylor,Andrew Saunders,Michael R Kurman,Olivier Hermine,Juan Carlos Ramos

doi:10.1200/jco.2014.32.15_suppl.tps8622

Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator’s choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL).

Adrienne Alise Phillips, Paul Fields + Show 12 more

https://doi.org/10.1200/jco.2014.32.15_suppl.tps8622

Copy DOI

Journal: Journal of Clinical Oncology

Publication Date: May 20, 2014

Affiliation: Columbia University, Guy's Hospital, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center, Kirin (United States), Albert Einstein College of Medicine, Centre Hospitalier Universitaire de Martinique, National Cancer Institute, St Mary's Hospital, Kyowa Kirin International (United Kingdom), Hôpital Necker-Enfants Malades, University of Miami

#Thymus- And Activation-regulated Chemokine #Refractory Adult T-cell Leukemia-lymphoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

TPS8622 Background: The receptor for macrophage derived chemokine (MDC) and thymus- and activation-regulated chemokine (TARC) CC chemokine receptor 4 (CCR4) is over expressed in several T-cell mali...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.